Linked Life Data

20062936

Source:http://linkedlifedata.com/resource/pubmed/id/20062936

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-1-11
pubmed:abstractText
Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In ACS, antiplatelet effects of a prasugrel MD regimen have not been previously compared with either a higher clopidogrel MD or after switching from a higher clopidogrel LD. The objective of this study was to evaluate the antiplatelet effect of a prasugrel 10-mg MD versus a clopidogrel 150-mg MD in patients with ACS who had received a clopidogrel 900-mg LD. Patients with non-ST elevation ACS, treated with aspirin and a clopidogrel 900-mg LD, were randomised within 24 hours post-LD to receive a prasugrel 10-mg or clopidogrel 150-mg MD. After 14 days of the initial MD, subjects switched to the alternative treatment for 14 days. The primary endpoint compared maximum platelet aggregation (MPA, 20 microM adenosine diphosphate [ADP]) between prasugrel and clopidogrel MDs for both periods. Responder analyses between treatments were performed using several platelet-function methods. Of 56 randomised subjects, 37 underwent PCI. MPA was 26.2% for prasugrel 10 mg and 39.1% for clopidogrel 150 mg (p<0.001). The prasugrel MD regimen reduced MPA from the post-900-mg LD level (41.2% to 29.1%, p=0.003). Poor response ranged from 0% to 6% for prasugrel 10 mg and 4% to 34% for clopidogrel 150 mg. Thus, in ACS patients a prasugrel 10-mg MD regimen resulted in significantly greater platelet inhibition than clopidogrel at twice its approved MD or a 900-mg LD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0340-6245
pubmed:author
pubmed:issnType
Print
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
213-23
pubmed:meshHeading
pubmed-meshheading:20062936-Acute Coronary Syndrome, pubmed-meshheading:20062936-Adenosine Diphosphate, pubmed-meshheading:20062936-Adult, pubmed-meshheading:20062936-Aged, pubmed-meshheading:20062936-Aged, 80 and over, pubmed-meshheading:20062936-Cross-Over Studies, pubmed-meshheading:20062936-Double-Blind Method, pubmed-meshheading:20062936-Female, pubmed-meshheading:20062936-Humans, pubmed-meshheading:20062936-Male, pubmed-meshheading:20062936-Middle Aged, pubmed-meshheading:20062936-Paris, pubmed-meshheading:20062936-Piperazines, pubmed-meshheading:20062936-Platelet Aggregation, pubmed-meshheading:20062936-Platelet Aggregation Inhibitors, pubmed-meshheading:20062936-Platelet Function Tests, pubmed-meshheading:20062936-Thiophenes, pubmed-meshheading:20062936-Ticlopidine, pubmed-meshheading:20062936-Time Factors, pubmed-meshheading:20062936-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
pubmed:affiliation
Institut de Cardiologie (AP-HP), INSERM U856 and Universite Paris 6, Hopital Pitié-Salpetrière, Paris, France. gilles.montalescot@psl.aphp.fr
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study